- Home
- RELI vs APRE Comparison
RELI vs APRE Comparison
Compare RELI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELI
- APRE
- Stock Information
- Founded
- RELI 2013
- APRE 2006
- Country
- RELI United States
- APRE United States
- Employees
- RELI N/A
- APRE N/A
- Industry
- RELI Specialty Insurers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RELI Finance
- APRE Health Care
- Exchange
- RELI Nasdaq
- APRE Nasdaq
- Market Cap
- RELI 7.5M
- APRE 8.3M
- IPO Year
- RELI N/A
- APRE 2019
- Fundamental
- Price
- RELI $1.01
- APRE $1.47
- Analyst Decision
- RELI
- APRE Strong Buy
- Analyst Count
- RELI 0
- APRE 1
- Target Price
- RELI N/A
- APRE $20.00
- AVG Volume (30 Days)
- RELI 11.7M
- APRE 40.4K
- Earning Date
- RELI 11-06-2025
- APRE 11-06-2025
- Dividend Yield
- RELI N/A
- APRE N/A
- EPS Growth
- RELI N/A
- APRE N/A
- EPS
- RELI N/A
- APRE N/A
- Revenue
- RELI $14,061,478.00
- APRE $841,012.00
- Revenue This Year
- RELI N/A
- APRE N/A
- Revenue Next Year
- RELI N/A
- APRE N/A
- P/E Ratio
- RELI N/A
- APRE N/A
- Revenue Growth
- RELI 1.07
- APRE N/A
- 52 Week Low
- RELI $0.67
- APRE $1.37
- 52 Week High
- RELI $5.11
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- RELI 53.73
- APRE 45.12
- Support Level
- RELI $0.89
- APRE $1.46
- Resistance Level
- RELI $1.15
- APRE $1.57
- Average True Range (ATR)
- RELI 0.21
- APRE 0.08
- MACD
- RELI 0.03
- APRE 0.01
- Stochastic Oscillator
- RELI 23.31
- APRE 54.45
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.